US$ 27.91
pharma news today obesity drugs glp-1 The Revolution: How Next-Generation Are Reshaping the Global Healthcare Market How Supply and Demand for
Description
Promotional availability and terms may change, so verify any codes at checkout to confirm they are currently active
M.SvalastogaP.MaloneyK
Liraglutide treatment in a patient with HIV, type 2 diabetes and sleep apnoea-hypopnoea syndrome

For instance, LEADER (liraglutide) excluded patients who had suffered a stroke or acute coronary syndrome (ACS) in the two weeks before recruitment [54], whereas SUSTAIN-6 set this exclusion window to 90 days prior [50]
The lawsuits allege inadequate warnings, not that the drugs should never have been approved
